Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

PBLA

Panbela Therapeutics Inc.

Nov 30 • 04:00PM ET

0.5300

Dollar change +0.0336
Percentage change 6.77	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-200.81	Insider Own	0.50%	Shs Outstand	-	Perf Week	3.72%
Market Cap	2.72M	Forward P/E	-	EPS next Y	-3.13	Insider Trans	-73.97%	Shs Float	5.10M	Perf Month	-35.21%
Income	-23.51M	PEG	-	EPS next Q	-1.23	Inst Own	8.88%	Short Float / Ratio	1.27% / 0.06	Perf Quarter	-61.87%
Sales	0.00M	P/S	-	EPS this Y	99.50%	Inst Trans	-	Short Interest	0.06M	Perf Half Y	-91.67%
Book/sh	-0.83	P/B	-	EPS next Y	69.50%	ROA	-303.48%	Target Price	20.50	Perf Year	-99.70%
Cash/sh	0.18	P/C	2.99	EPS next 5Y	-	ROE	-798.16%	52W Range	0.48 - 295.20	Perf YTD	-99.40%
Dividend	-	P/FCF	-	EPS past 5Y	10.22%	ROI	-1374.17%	52W High	-99.82%	Beta	0.74
Dividend %	-	Quick Ratio	0.21	Sales past 5Y	0.00%	Gross Margin	-	52W Low	10.42%	ATR	0.10
Employees	7	Current Ratio	0.21	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	36.63	Volatility	14.87% 17.77%
Optionable	No	Debt/Eq	-	EPS Q/Q	98.94%	Profit Margin	-	Rel Volume	0.33	Prev Close	0.50
Shortable	Yes	LT Debt/Eq	-	Earnings	Nov 09 AMC	Payout	-	Avg Volume	1.06M	Price	0.53
Recom	1.00	SMA20	-15.59%	SMA50	-40.08%	SMA200	-93.41%	Volume	351,885	Change	6.77%

Nov-29-23 08:15AM	Panbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial Modification (GlobeNewswire)
Nov-09-23 04:10PM	Panbela Provides Business Update and Reports Q3 2023 Financial Results (GlobeNewswire) -13.13%
Nov-03-23 07:55AM	Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds Priced At-the-Market (GlobeNewswire) -24.19%
Nov-02-23 08:15AM	Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves Cell Function in Type 1 Diabetes (GlobeNewswire) +19.27%
Oct-31-23 08:15AM	Panbela Announces Validation of European Patent in UK, Italy, Germany, France, and Spain for Claims of a Novel Process for the Production of SBP-101 (GlobeNewswire)
08:15AM	Loading…
Oct-25-23 08:15AM	Acceptance of Polyamine Inhibitor CAR-T Combination Abstract for Online Publication (GlobeNewswire)
Oct-24-23 08:15AM	Panbela to Host Third Quarter 2023 Earnings Conference Call on November 9, 2023 (GlobeNewswire)
Sep-26-23 08:15AM	Panbela Announces Issuance of New Patent in China for Claims of a Novel Process for the Production of SBP-101 (GlobeNewswire)
Sep-19-23 08:15AM	Panbela to Present at the LD Micro Investor Conference (GlobeNewswire)
Sep-05-23 08:15AM	Panbela Announces Issuance of New Patent in Chile for Claims of a Novel Process for the Production of Flynpovi (GlobeNewswire)
Aug-28-23 08:15AM	Panbela to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-14-23 08:15AM	Panbela Announces Issuance of New Patent in Europe for Claims of a Novel Process for the Production of SBP-101 (GlobeNewswire)
Aug-13-23 08:55AM	Panbela Therapeutics, Inc. (NASDAQ:PBLA) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 04:10PM	Panbela Provides Business Update and Reports Q2 2023 Financial Results (GlobeNewswire)
Jul-31-23 04:15PM	Panbela to Host Second Quarter 2023 Earnings Conference Call on August 10, 2023 (GlobeNewswire)
08:15AM	Loading…
Jul-24-23 08:15AM	Panbela Opens Enrollment in UK and Germany for Aspire Trial in Pancreatic Cancer, All Countries/Regions in the Aspire Trial are Now Open and Actively Enrolling (GlobeNewswire) -5.07%
Jul-19-23 08:00AM	Panbela Therapeutics to Receive a Total Up to $9.5 Million for Divestiture of Assets within Eflornithine (DFMO) Pediatric Neuroblastoma Program to US WorldMeds (GlobeNewswire)
Jul-17-23 06:00AM	Panbela Announces Issuance of New Patent in Australia Patent is for Claims of a Novel Process for the Production of SBP-101 (GlobeNewswire)
Jul-10-23 08:15AM	Panbela Announces Preliminary Safety Analysis for ASPIRE Trial (GlobeNewswire) +10.70%
Jun-28-23 08:15AM	Panbela Announces PACES S0820 Phase III Trial Passes Pre-Planned Futility Analysis (GlobeNewswire) +7.77%
Jun-26-23 08:15AM	Panbela Announces Poster Presentation at the Endocrine Society Meeting: Polyamine Inhibition and -Cell Preservation in Recent Onset Type 1 Diabetes (GlobeNewswire) -8.48%
Jun-21-23 04:15PM	Panbela Announces Closing of Approximately $8.5 Million Public Offering (GlobeNewswire)
Jun-16-23 08:15AM	Panbela Announces Pricing of Approximately $8.5 Million Public Offering (GlobeNewswire) -55.25%
Jun-13-23 08:15AM	Panbela Announces Sponsored Research Agreement to Evaluate Polyamine Metabolic Inhibitor Therapy in Combination with CAR-T Cell Therapy (GlobeNewswire) -5.38%
Jun-01-23 08:15AM	Panbela Announces Poster Presentation at Immunology of Diabetes Society Meeting: Evaluating the Potential of CPP-1X (Eflornithine) in Recent Onset Type 1 Diabetes (GlobeNewswire) -5.82%
May-31-23 08:00AM	Panbela Announces 1-for-30 Reverse Stock Split Effective June 1, 2023 (GlobeNewswire) -33.79%
May-22-23 08:15AM	Panbela Announces Clinical Trial with Moffitt Cancer Center for Phase I/II Program in STK11 Mutant Non-Small Cell Lung Cancer (GlobeNewswire)
May-04-23 04:10PM	Panbela Provides Business Update and Reports Q1 2023 Financial Results (GlobeNewswire) -7.27%
Apr-24-23 08:15AM	Panbela to Host First Quarter 2023 Earnings Conference Call on May 4, 2023 (GlobeNewswire) -9.95%
Apr-19-23 08:15AM	Panbela Announces Poster Presentation at American Association for Cancer Research: Evaluating the potential of spermine analogue ivospemin (SBP-101) in combination with chemotherapy in ovarian cancer (GlobeNewswire) -13.62%
08:15AM	Loading…
Apr-12-23 08:15AM	First Patient Enrolled in JDRF-Funded Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, Led by Indiana University School of Medicine (GlobeNewswire) +29.33%
Apr-11-23 08:15AM	Panbela Regains Worldwide Rights to Develop and Commercialize FlynpoviTM in Patients with Familial Adenomatous Polyposis (FAP) (GlobeNewswire)
Apr-10-23 08:30AM	Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Immunology of Diabetes Society Meeting (GlobeNewswire) +16.16%
Apr-06-23 08:30AM	Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Endocrine Society Meeting (GlobeNewswire) +8.43%
Apr-03-23 08:30AM	Panbela Announces New Research Agreement with Johns Hopkins University School of Medicine (GlobeNewswire) -5.47%
Mar-22-23 08:30AM	Panbela Announces Issuance of New Patent in Japan; Patent is for Claims of a Novel Process for the Production of SBP-101 (GlobeNewswire)
Mar-18-23 10:29AM	When Will Panbela Therapeutics, Inc. (NASDAQ:PBLA) Become Profitable? (Simply Wall St.)
Mar-16-23 04:10PM	Panbela Provides Business Update and Reports Q4 and FY 2022 Financial Results (GlobeNewswire)
Mar-08-23 08:00AM	Panbela to Host Fourth Quarter and Year End 2022 Earnings Conference Call on March 16, 2023 (GlobeNewswire) -5.77%
Mar-07-23 08:00AM	Panbela Announces First Patient Enrolled in South Korea for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire) -8.24%
Mar-01-23 08:30AM	Acceptance of SBP-101 Abstract for Poster Presentation at American Association for Cancer Research (AACR) (GlobeNewswire) -26.28%
Feb-13-23 08:30AM	Panbela Announces Closing of Approximately $15 Million Public Offering, and Regains Compliance with Nasdaq Listing Standards (GlobeNewswire) +11.45%
Jan-26-23 08:41AM	Panbela Announces Pricing of Approximately $15 Million Public Offering (GlobeNewswire) -40.59%
Jan-19-23 09:00AM	Panbela Announces Adoption of Commission Implementing Decision from the EMA for the Orphan Designation of Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire)
Jan-12-23 11:00AM	Panbela Announces 1-for-40 Reverse Stock Split effective January 13, 2023 (GlobeNewswire) -8.57%
Jan-11-23 09:00AM	Panbela Starts Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, in Collaboration with Indiana University School of Medicine and JDRF (GlobeNewswire)
Dec-14-22 09:00AM	Panbela Receives Positive EMA Opinion on Orphan Designation for Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire) -13.31%
Nov-28-22 09:00AM	Panbela Announces First Patients Enrolled in Europe for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire) -5.66%
Nov-10-22 04:10PM	Panbela Provides Business Update and Reports Q3 2022 Financial Results (GlobeNewswire)
Oct-31-22 09:00AM	Panbela Schedules Conference Call on, November 10, 2022, to Report 2022 Third Quarter Financial Results (GlobeNewswire) -7.87%
Oct-06-22 08:00AM	Panbela to Participate in the Roth Inaugural Healthcare Opportunities Conference (GlobeNewswire)
Sep-30-22 08:37AM	Panbela Announces Pricing of Approximately $6 Million Public Offering (GlobeNewswire) -24.71%
Sep-29-22 09:00AM	Panbela Receives Approvals to Open Trial Sites in Spain, France and Italy for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire)
Aug-15-22 04:10PM	Panbela Provides Business Update and Reports Q2 2022 Financial Results (GlobeNewswire) -7.71%
Aug-11-22 09:00AM	Panbela Announces First Patient Enrolled in its Aspire Trial Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire)
Aug-04-22 09:00AM	Panbela Expands Aspire Trial to Australia, Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire)
Aug-01-22 04:00PM	Panbela Schedules Conference Call on, August 15, 2022, to Report 2022 Second Quarter Financial Results (GlobeNewswire)
Jun-28-22 08:00AM	Panbela Announces Publication of Preclinical Data Titled: Expanded Potential of the Polyamine Analogue SBP-101 (Diethyl Dihydroxyhomospermine) as a Modulator of Polyamine Metabolism and Cancer Therapeutic (GlobeNewswire)
Jun-16-22 08:00AM	Panbela Therapeutics, Inc. Closes Acquisition of Cancer Prevention Pharmaceuticals, Inc. (GlobeNewswire) +5.56%
May-12-22 04:05PM	Panbela Provides Business Update and Reports Q1 2022 Financial Results (GlobeNewswire)
Apr-27-22 08:30AM	Panbela to Host Virtual R&D Day (GlobeNewswire) -6.11%
Apr-26-22 08:30AM	Panbela Schedules Conference Call on May 12, 2022, to Report 2022 First Quarter Financial Results (GlobeNewswire)
Apr-12-22 08:30AM	Panbela Announces Poster Presentation at American Association for Cancer Research: (GlobeNewswire) -6.49%
Mar-24-22 04:05PM	Panbela Provides Business Update and Reports Q4 and FY 2021 Financial Results (GlobeNewswire)
Mar-23-22 08:30AM	Panbela to Participate in a Panel Discussion: Pancreatic Cancer- Turning the Tide for One of the Most Challenging Indications in Oncology, at the Maxim Virtual Growth Conference on March 28, 2022, at 12:00 pm ET (GlobeNewswire) +7.89%
Mar-10-22 08:30AM	Panbela to Participate in the 34th Annual Roth Conference (GlobeNewswire)
Mar-08-22 08:30AM	Panbela Schedules Conference Call on March 24, 2022, to Report 2021 Fourth Quarter Financial Results (GlobeNewswire)
Mar-07-22 08:30AM	Acceptance of SBP-101 Abstract for Poster Presentation at American Association for Cancer Research (AACR) (GlobeNewswire)
Feb-22-22 08:00AM	Panbela Therapeutics, Inc. to Acquire Cancer Prevention Pharmaceuticals, Inc. (GlobeNewswire) -8.80%
Jan-26-22 09:00AM	Panbela Initiates a Randomized, Double-Blind, Placebo-Controlled Study (ASPIRE) of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire) +7.50%
Jan-24-22 09:00AM	Panbela Presents Clinical Data on Phase 1b Clinical Trial of SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic PDA at 2022 ASCO GI Meeting (GlobeNewswire)
Dec-14-21 09:00AM	Panbela Announces Positive Preclinical Data Strongly Supporting the Activity of SBP-101 in Ovarian Cancer Cell Lines; Development Program for SBP-101s Expansion into Ovarian Cancer Expected in 1H 2022 (GlobeNewswire)
Nov-18-21 09:00AM	Panbela Announces Acceptance of Abstract for Poster Presentation at American Society of Clinical Oncology Gastrointestinal Cancers Symposium (GlobeNewswire) -5.31%
Nov-10-21 04:15PM	Panbela Provides Business Update and Reports Q3 2021 Financial Results (GlobeNewswire)
Oct-25-21 09:00AM	Panbela Schedules Conference Call on November 10, 2021, to Report 2021 Third Quarter Financial Results (GlobeNewswire)
Sep-27-21 01:08PM	We're Keeping An Eye On Panbela Therapeutics' (NASDAQ:PBLA) Cash Burn Rate (Simply Wall St.)
Sep-07-21 09:00AM	Panbela to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-11-21 04:12PM	Panbela Provides Business Update and Reports Q2 2021 Financial Results (GlobeNewswire)
Aug-09-21 08:00AM	Panbela Announces Issuance of key U.S. Patent; Patent is for Claims of a Novel Process for the Production of SBP-101 (GlobeNewswire)
Jul-28-21 09:00AM	Panbela Schedules Conference Call on August 11, 2021, to Report 2021 Second Quarter Financial Results (GlobeNewswire) +11.76%
Jul-08-21 11:20AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 (ACCESSWIRE)
Jul-07-21 08:45AM	Panbela to Present at Access to Giving Virtual Conference on July 15, 2021, at 10:30 a.m. ET (GlobeNewswire)
Jul-02-21 04:05PM	PANBELA THERAPEUTICS ANNOUNCES CLOSING OF $10.0 MILLION BOUGHT DEAL OFFERING OF COMMON STOCK (GlobeNewswire)
Jun-30-21 12:06AM	PANBELA THERAPEUTICS INCREASES PREVIOUSLY ANNOUNCED BOUGHT DEAL OFFERING OF COMMON STOCK TO $10.0 MILLION (GlobeNewswire) -25.92%
Jun-29-21 05:25PM	PANBELA THERAPEUTICS ANNOUNCES $5.0 MILLION BOUGHT DEAL OFFERING OF COMMON STOCK (GlobeNewswire) -6.14%
Jun-23-21 09:35AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 (ACCESSWIRE)
Jun-08-21 05:07PM	Panbela Set to Join Russell Microcap® Index (GlobeNewswire)
Jun-04-21 09:15AM	Panbela Presents Clinical Data on Phase 1b Clinical Trial of SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic PDA at 2021 ASCO Annual Meeting (GlobeNewswire) -10.15%
May-26-21 08:00AM	Panbela Announces Company Founder Dr. Michael T. Cullen to Serve as Chairman of the Board of Directors (GlobeNewswire)
May-12-21 04:10PM	Panbela Provides Business Update and Reports Q1 2021 Financial Results (GlobeNewswire)
02:30PM	Panbela Therapeutics, Inc. to Host Earnings Call (ACCESSWIRE)
Apr-28-21 08:00AM	Panbela Schedules Conference Call on May 12, 2021 to Report 2021 First Quarter Financial Results (GlobeNewswire)
Apr-15-21 08:00AM	Panbela Announces Partial Clinical Hold Lifted on Phase I Polyamine Metabolic Inhibitor Study in Pancreatic Cancer (GlobeNewswire)
Apr-06-21 08:15AM	Panbela Announces Acceptance of Abstract for Poster Presentation at American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
Mar-29-21 07:37AM	Companies Like Panbela Therapeutics (NASDAQ:PBLA) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-26-21 08:40AM	Corrected: Panbela Provides Business Update and Reports Q4 and FY 2020 Financial Results (GlobeNewswire)
Mar-25-21 04:30PM	Panbela Therapeutics, Inc. to Host Earnings Call (ACCESSWIRE)
04:10PM	Panbela Provides Business Update and Reports Q4 and FY 2020 Financial Results (GlobeNewswire)
Mar-17-21 06:02PM	Panbela Schedules Conference Call on March 25, 2021 to Report 2020 Fourth Quarter Financial Results (GlobeNewswire)
Mar-15-21 08:00AM	Panbela Appoints Industry Veteran, Garry A. Weems, PharmD, as Vice President of Clinical Development & Medical Affairs (GlobeNewswire)

Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firm's product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types. The company was founded by Michael T. Cullen, Jr. and Thomas X. Neenan on September 21, 2011 and is headquartered in Waconia, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GOLDMAN SACHS GROUP INC	10% Owner	Nov 08	Sale	0.71	72,874	51,741	397,954	Nov 13 07:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PBLA

Panbela Therapeutics Inc.

Upgrade your FINVIZ experience